The company was founded in February 1988 by Mr. Rainer C. Burian who has served as PAA’s CEO since then. The company is set up in Austria's first technology centre in Linz. Responsible investment manager is Mr. Andreas Mladek who joined PAA Laboratories as managing partner and CFO in 1992. | 1988 |
Mr. Harry Brack, is put in charge of setting up PAA’s subsidiary in Germany. In the same year PAA UK is founded. | 1992 |
A research unit is founded in Munich in order to further pursue PAA’s UV-C virus inactivation technology by optimizing the process and constructing the world’s first computerized and patented machine to inactivate viruses and mycoplasma in serum. Dr. Rainer Waldmann joins as PAA's Technical Director. He is now the President of the Australian operation (since 2005). | 1997 |
PAA France is set up in Les Mureaux, a suburb of Paris. | 2000 |
A decision is taken to build a new production plant in Austria in order to meet the strong growing demand for sera and media. An existing, suitable factory was purchased and converted into a high-tech GMP certified pharmaceutical production plant - the most modern of its kind in Europe at the moment. The investment totalled app. US$ 15 million. | 2001 |
On October 31, 2003 the new manufacturing plant was inaugurated in the presence of several hundred invited guests. The year was highlighted by two company prizes. PAA is selected out of 450 competitors for “Austrian’s Leading Mid-Sized Company” prize (ALC) and sited as being the most successful company in terms of three years growth of sales and cash flow. PAA also wins Upper Austrian’s “Golden Pegasus” prize, underlining the company’s successful development. | 2003 |
PAA has now become a genuine global player. With the acquisition of Cansera, Toronto and Serum Ventures, Australia the company distributes its range of products to the most distant points of sales worldwide. PAA has become one of only three vertically integrated companies with their own raw material sourcing and collection and with GMP processing facilities on three different continents. Industrial buyers can now get high quality final filtered products directly from the country where the raw material was collected. PAA Austria is the first company in the cell culture reagents business to be granted a GMP pharmaceutical manufacturing license for “in-vivo products for tissue cultures”. Under this license, PAA begins the manufacture of Advanced Therapy Medicinal Products (ATMP-Ready) to meet the specialised requirements for cell culture products used in Advanced Therapies. | 2005 |
PAA USA is founded in order to meet the challenges of the largest single market of the world. Located in the Greater Boston area, products can now easily be shipped to industrial and research customers all over the Americas. | 2006 |
Mr. Harry Brack and Mr. Rainer Waldmann, longtime associates and members of the board of directors became share-holders of PAA along with Mr. Rainer Burian and Mr. Andreas Mladek. PAA continues to develop new products and expanded its portfolio. Of special note are:
PAA posesses also the technical and scientific know-how to satisfy customer specific requirements in terms of special product manufacturing and customized fillings. A variety of customized packaging options are available in sizes from 20 ml bottles to 20 litres bags. | 2008 |
The Austrian plant is enlarged to 10.000m² by building new warehouses, offices, an R&D lab and a dry powder media production facility. Two air classification mills and four screw cone blenders produce powder media in batch sizes from 0.7 to 8.000 kg, offering the largest batch size of the entire industry. | 2009 |
Since October 2011 PAA Laboratories is part of GE Healthcare, a leading global provider of transformational medical technologies and services. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE) with approx. $17 billion in global sales. 46,000 GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. | 2011 |
Change Settings
Current selection:
Worldwide
Worldwide